** Shares of LTR Pharma rise 7.9% to A$0.755
** The biopharmaceutical firm rose as much as 17.9% earlier in the day, their biggest intraday gain since early November
** Co enters an agreement with Australian pharmaceutical wholesaler Symbion for nation-wide distribution for SPONTAN
** SPONTAN is LTR Pharma's lead product for treatment of erectile dysfunction
** About 1.2 mln shares change hands, compared with 30-day average trading volume of 669,941 shares
** Stock down 13.6% YTD, as of last close
(Reporting by John Biju in Bengaluru)
((John.Biju@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。